The present invention refers to novel UV-light cleavable drug conjugates comprising a diazirine linker.

The present invention refers to novel UV-light cleavable drug conjugates comprising a diazirine linker.

The present invention relates to novel chemical compounds of indane-, indene-, azaindane-, and azaindene-amines that act as 5-HT2A receptor agonists. These compounds are designed to offer improved therapeutic profiles for the treatment of a variety of neuropsychiatric, neurological, and neurodegenerative disorders. Also disclosed are methods for the synthesis and pharmaceutical use of these compounds.

Organic compounds for target identification, drug discovery, chemical library production, high-throughput screening, fluorophore conjugation, chemiluminescent compound conjugation, creation of proximity induced modulators (e.g., protein degraders)/chimeric molecules, or a combination thereof are described. The compounds can contain small molecule moieties for identification of their potential targets; an isocyanate, photoactivatable groups; chemical moieties for enrichment and detection of target-small molecule moiety interactions; proximity induced modulator element; fluorophores; chemiluminescent groups; or combinations thereof.

Organic compounds for target identification, drug discovery, chemical library production, high-throughput screening, fluorophore conjugation, chemiluminescent compound conjugation, creation of proximity induced modulators (e.g., protein degraders)/chimeric molecules, or a combination thereof are described. The compounds can contain small molecule moieties for identification of their potential targets; an isocyanate, photoactivatable groups; chemical moieties for enrichment and detection of target-small molecule moiety interactions; proximity induced modulator element; fluorophores; chemiluminescent groups; or combinations thereof.